EXTON, Pa., Nov. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated
(Nasdaq: VPHM) today announced that Vincent Milano, president and chief
executive officer of ViroPharma, will present at the Rodman & Renshaw Annual
Global Investment Conference at 12:25 P.M. ET on Wednesday, November 12, 2008.
The conference is being held at the New York Palace Hotel.
ViroPharma also announced that Colin Broom, vice president, chief
scientific officer of ViroPharma will present at the Lazard Capital Markets
5th Annual Healthcare Conference at 9:30 A.M. ET on Wednesday, November 19,
2008. The conference is being held at the St. Regis Hotel in New York.
William Roberts, vice president, corporate communications of ViroPharma
will present at the Needham & Company Focus on Infectious Disease Conference
at 9:30 A.M. ET on Thursday, November 20, 2008. The conference is being held
at Needham & Company's corporate headquarters in New York.
ViroPharma's presentations will be webcast live for investors through
www.viropharma.com and available for a period of 14 days following the
conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the
development and commercialization of products that address serious diseases
treated by physician specialists and in hospital settings. ViroPharma
commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved
for oral administration for treatment of antibiotic-associated
pseudomembranous colitis caused by Clostridium difficile and enterocolitis
caused by Staphylococcus aureus, including methicillin-resistant strains, and
Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema
attacks in adolescent and adult patients with hereditary angioedema (HAE),
also known as C1 inhibitor deficiency (for prescribing information on
ViroPharma's commercial products, please download the package inserts at
http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its
drug development activities in diseases including cytomegalovirus (CMV), HAE
and C. difficile.
ViroPharma routinely posts information, including press releases, which
may be important to investors in the investor relations and media sections of
our company's web site, www.viropharma.com. The company encourages investors
to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated
